

**Oklahoma Health Care Authority  
Drug Utilization Review Board**

(DUR Board)

**Meeting – September 14, 2011 @ 6:00 p.m.**

Oklahoma Health Care Authority  
2401 N.W. 23<sup>rd</sup> Street, Suite 1-A  
Oklahoma City, Oklahoma 73107  
Ponca Room (North Entrance)

---

**AGENDA**

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

1. **Call To Order**
  - A. Roll Call – Dr. Graham

Items to be presented by Dr. Muchmore, Chairman:

2. **Public Comment Forum**
  - A. Acknowledgment of Speakers and Agenda Items

Items to be presented by Dr. Muchmore, Chairman:

3. **Action Item – Approval of DUR Board Meeting Minutes – See Appendix A.**
  - A. August 10, 2011 DUR Minutes – Vote
  - B. August 11, 2011 DUR Recommendation Memorandum

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman:

4. **Update on DUR / Medication Coverage Authorization Unit – See Appendix B.**
  - A. Retrospective Drug Utilization Review for May 2011
  - B. Retrospective Drug Utilization Review Response for April 2011
  - C. Medication Coverage Activity Audit for August 2011
  - D. Pharmacy Help Desk Activity Audit for August 2011

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman:

5. **Action Item – Vote to Prior Authorize Diabetes Medications – See Appendix C.**
  - A. COP Recommendations

Items to be presented by Dr. Le, Dr. Muchmore, Chairman:

6. **Action Item – Vote to Prior Authorize Xiaflex<sup>®</sup> – See Appendix D.**
  - A. COP Recommendations

Items to be presented by Dr. Moore, Dr. Muchmore, Chairman:

7. **Action Item – Vote to Prior Authorize Berinert<sup>®</sup>, Cinryze<sup>®</sup>, and Kalbitor<sup>®</sup> – See Appendix E.**
  - A. Drug Information
  - B. COP Recommendations

Items to be presented by Dr. Moore, Dr. Muchmore, Chairman

8. **30 Day Notice to Prior Authorize Firazyr<sup>®</sup> – See Appendix F.**
  - A. Product Summary
  - B. COP Recommendations
  - E. Product Details

Items to be presented by Dr. Sipols, Dr. Muchmore, Chairman

9. **60 Day Notice to Prior Authorize Biologic Products for the Treatment of Rheumatoid Arthritis, Crohn's Disease, Plaque Psoriasis, and Ankylosing Spondylitis – See Appendix G.**
  - A. Member Demographics
  - B. Market Analysis by Claims and Indication
  - C. Product Costs
  - D. Market News and Updates
  - E. Economic Impact
  - F. COP Recommendations

Items to be presented by Dr. Le, Dr. Muchmore, Chairman

10. **Drug Utilization Review of Multiple Sclerosis Medications – See Appendix H.**
  - A. Treatment of Multiple Sclerosis
  - B. Utilization Review
  - C. Market Trends
  - D. Other Considerations in Treatment of Multiple Sclerosis
  - E. COP Recommendations

Items to be presented by Dr. Moore, Dr. Muchmore, Chairman

11. **Action Item – Annual Review of Synagis<sup>®</sup> – See Appendix I.**
  - A. Current Authorization Criteria
  - B. Utilization Review
  - C. Prior Authorization Review
  - D. Utilization Details
  - E. COP Recommendations

Items to be presented by Dr. Graham, Dr. Muchmore, Chairman

12. **FDA and DEA Updates – See Appendix J.**
  
13. **Future Business**
  - A. Annual Review of Pediculicides
  - B. Annual Review of Ophthalmic Antibiotics
  - C. New Product Reviews
  - D. Medical Product Reviews

14. **Adjournment**